Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016, Article ID 1523959, 6 pages
http://dx.doi.org/10.1155/2016/1523959
Research Article

The Prognostic Significance of Beta2 Microglobulin in Patients with Hemophagocytic Lymphohistiocytosis

1Department of Cardiology, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing 100029, China
2Departments of Clinical Laboratory, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China

Received 12 January 2016; Accepted 6 March 2016

Academic Editor: Michele Malaguarnera

Copyright © 2016 Tiantong Jiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. E. Janka, “Hemophagocytic syndromes,” Blood Reviews, vol. 21, no. 5, pp. 245–253, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. F. G. N. Rosado and A. S. Kim, “Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis,” American Journal of Clinical Pathology, vol. 139, no. 6, pp. 713–727, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. S. F. N. Bode, K. Lehmberg, A. Maul-Pavicic et al., “Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis,” Arthritis Research and Therapy, vol. 14, no. 3, p. 213, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Ishii, S. Ohga, S. Imashuku et al., “Nationwide survey of hemophagocytic lymphohistiocytosis in Japan,” International Journal of Hematology, vol. 86, no. 1, pp. 58–65, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Machaczka, J. Vaktnäs, M. Klimkowska, and H. Hägglund, “Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center,” Leukemia and Lymphoma, vol. 52, no. 4, pp. 613–619, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Bladé, M. T. Cibeira, C. Fernández de Larrea, and L. Rosiñol, “Multiple myeloma,” Annals of Oncology, vol. 21, supplement 7, pp. 313–319, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Z. Penz, W. C. C. Fiebiger, J. B. Valencak et al., “Beta-2-microglobulin levels in patients with extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type: a retrospective analysis,” Anticancer Research, vol. 21, no. 4, pp. 3049–3052, 2001. View at Google Scholar · View at Scopus
  8. T. P. Vassilakopoulos, G. Nadali, M. K. Angelopoulou et al., “The prognostic significance of beta (2)-microglobulin in patients with Hodgkin's lymphoma,” Haematologica, vol. 87, no. 7, pp. 701–708, 2002. View at Google Scholar
  9. S. Shinkai, P. H. M. Chaves, Y. Fujiwara et al., “β2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein,” Archives of Internal Medicine, vol. 168, no. 2, pp. 200–206, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Hibi, S. Ikushima, F. Fujiwara et al., “Serum and urine beta-2-microglobulin in hemophagocytic syndrome,” Cancer, vol. 75, no. 7, pp. 1700–1705, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. J.-I. Henter, A. Horne, M. Aricó et al., “HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis,” Pediatric Blood and Cancer, vol. 48, no. 2, pp. 124–131, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. S. H. Swerdlow, E. Campo, N. L. Harris et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC, Lyon, France, 4th edition, 2008.
  13. Y. W. Koh, H. J. Kang, C. Park et al., “Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic hodgkin lymphoma,” American Journal of Clinical Pathology, vol. 138, no. 6, pp. 846–854, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. S. A. Parikh, P. Kapoor, L. Letendre, S. Kumar, and A. P. Wolanskyj, “Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis,” Mayo Clinic Proceedings, vol. 89, no. 4, pp. 484–492, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Yoo, D. H. Yoon, and C. Suh, “Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor,” Blood Research, vol. 49, no. 3, pp. 148–153, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Shi, Y. Zhu, Y. Su, L. W. K. Chung, and T. Cheng, “β2-Microglobulin: emerging as a promising cancer therapeutic target,” Drug Discovery Today, vol. 14, no. 1-2, pp. 25–30, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. Z.-M. Li, Y.-J. Zhu, J. Sun et al., “Serum beta2-microglobin is a predictor of prognosis in patients with upper aerodigestive tract NK/T-cell lymphoma,” Annals of Hematology, vol. 91, no. 8, pp. 1265–1270, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Aulbert and O. Steffens, “Beta 2 microglobulin in serum—a ‘tumor marker’ in malignant lymphomas?” Medizinische Klinik, vol. 85, no. 1, pp. 13–17, 1990. View at Google Scholar
  19. S. Alici, S. E. Bavbek, E. Kaytan, Y. Eralp, and H. Onat, “Prognostic factors in localized aggressive non-Hodgkin's lymphoma,” American Journal of Clinical Oncology, vol. 26, no. 1, pp. 1–5, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. J. E. Romaguera, L. Fayad, M. A. Rodriguez et al., “High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine,” Journal of Clinical Oncology, vol. 23, no. 28, pp. 7013–7023, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. A. López-Guillermo, L. Colomo, M. Jiménez et al., “Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin,” Journal of Clinical Oncology, vol. 23, no. 12, pp. 2797–2804, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. G. M. Chronowski, R. B. Wilder, S. L. Tucker et al., “An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease,” Cancer, vol. 95, no. 12, pp. 2534–2538, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Swan Jr., W. S. Velasquez, S. Tucker et al., “A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels,” Journal of Clinical Oncology, vol. 7, no. 10, pp. 1518–1527, 1989. View at Google Scholar · View at Scopus
  24. P. Möller, B. Herrmann, G. Moldenhauer, and F. Momburg, “Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy,” International Journal of Cancer, vol. 40, no. 1, pp. 32–39, 1987. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Mori, Y. Terui, M. Ikeda et al., “β2-microglobulin identified as an apoptosis-inducing factor and its characterization,” Blood, vol. 94, no. 8, pp. 2744–2753, 1999. View at Google Scholar · View at Scopus
  26. M. Mori, Y. Terui, M. Tanaka et al., “Antitumor effect of beta2-microglobulin in leukemic cell-bearing mice via apoptosis-inducing activity: activation of caspase-3 and nuclear factor-kappaB,” Cancer Research, vol. 61, no. 11, pp. 4414–4417, 2001. View at Google Scholar · View at Scopus
  27. H. Trottestam, E. Berglöf, A. Horne et al., “Risk factors for early death in children with haemophagocytic lymphohistiocytosis,” Acta Paediatrica, vol. 101, no. 3, pp. 313–318, 2012. View at Publisher · View at Google Scholar · View at Scopus